ABSTRACT Incubation of cultured human umbilical vein endothelial cells with -4C]-arachidonic acid, followed by RP-HPLC analysis, resulted in the appearance of two principal radioactive products besides 6-keto-PGF,. The first peak was HHT, a hydrolysis product of the prostaglandin endoperoxide. The second peak was esterified, converted to the trimethylsilyl ether derivative, and analyzed by GC/MS and was shown to be the lipoxygenase product 1 5-HETE. Stimulation of endothelial cells with thrombin enhanced 15-HETE synthesis from arachidonate. Subsequent experiments showed that 5-HETE and 12-HETE were also synthesized by endothelial cells, but no evidence of leukotriene synthesis was found. Incubation of the 15-HETE precursor 1 5-HPETE with endothelial cells resulted in the formation of four distinct ultraviolet light-absorbing peaks. Ultraviolet and GC/MS analysis showed these peaks to be 8, 15-diHETEs that differed only in their hydroxyl configuration and cis-trans double-bond geometry. Formation of 8,15-diHETE molecules suggests the prior formation of the unstable epoxide molecule 14,15-LTA4 or an attack at C-10 of 15-HPETE by an enzyme with mechanistic features in common with a 12-lipoxygenase. The observation that endothelial cells can synthesize both 15-HETE and 8,15-diHETE molecules suggests that this cell type contains both a 15-lipoxygenase and a system that can synthesize 14,15-LTA4. Circulation 72, No. 4, 708-712, 1985. PG12* is the principal prostaglandin biosynthesized by cultured human umbilical vein endothelial cells in response to thrombin, histamine, A-23 187, trypsin, and ATP. LTC4 and LTD4 were shown to stimulate PGI2 biosynthesis in human endothelial cells, and agonist-specific desensitization to LTC4 was also observed.6. 7 Although leukotrienes are known to stimulate prostaglandin biosynthesis in endothelial cells, no physical evidence of arachidonate lipoxygenation by endothelial cells has appeared. In this report we present evidence that human umbilical vein endothelial cells do contain a 15-lipoxygenase.
PG12* is the principal prostaglandin biosynthesized by cultured human umbilical vein endothelial cells in response to thrombin, histamine, A-23 187, trypsin, and ATP. '-5 Recently, LTC4 and LTD4 were shown to stimulate PGI2 biosynthesis in human endothelial cells, and agonist-specific desensitization to LTC4 was also observed.6. 7 Although leukotrienes are known to stimulate prostaglandin biosynthesis in endothelial cells, no physical evidence of arachidonate lipoxygenation by endothelial cells has appeared. In this report we present evidence that human umbilical vein endothelial cells do contain a 15-lipoxygenase. Address for correspondence: R. R. Gorman, Ph.D., Cell Biology Department, The Upjohn Co., Kalamazoo, MI 49008.
*Abbreviations used are as follows: PGIh, prostaglandin b; LTC4, 5 (S) -hydroxy,6(R) -S-glutathionyl -7 -9-trans-1 1,14-cis-eicosatetraenoic acid; LTD4, 5(S)-hydroxy, 6 (R)-S-cysteinylglycine-7,9-trans-11, 14-cis-eicosatetraenoic acid; LTB4, [5(S) Culture of endothelial cells. Endothelial cells were derived from human umbilical cord veins as described by Jaffe et al.9 Cells were exposed to an atmosphere of 95% air and 5% CO2 and were fed twice a week until they were subcultured. Confluency was usually reached in 4 to 5 days.
Incubation of endothelial cells with arachidonic acid or 15-HPETE. Before the incubation of cells with arachidonate or 15-HPETE, the confluent monolayers were harvested from the culture flasks by a 5 min incubation with a 1:1 mixture of 0.2% collagenase: 0.5% bovine serum albumin, 0.02% EDTA. After washing, the cells were resuspended in cord buffer (137 mM Purification of reverse-phase peaks by HPLC. Monohydroxy and dihydroxy fatty acids collected from RP-HPLC were methylated with etheral diazomethane and the resulting methyl esters were dissolved in hexane with sonication. Purification of dihydroxy and monohydroxy fatty acids was achieved on a Bakerbond chiral column (4.6 mm x 25 cm) (J. T. Baker Research Products, Phillipsburg, NJ). Monohydroxy fatty acids were eluted isocratically in hexane/2-propanol (98:2) at a flow rate of 1.5 ml/min with ultraviolet detection at 235 nm. Dihydroxy fatty acids were isocratically eluted at 2.0 ml/min with hexane/2-propanol (96:4), with ultraviolet detection at 270 nm.
GC/MS of purified products. The purified methyl esters of the monohydroxy and dihydroxy fatty acids were derivatized with bis-(trimethylsilyl) trifluoroacetamide/1% trimethyl-chlorosilane (Pierce Chemical Company, Rockford, IL) and analyzed by GC/MS, as previously described." 
Results
Incubation of human endothelial cells (30 x 106) with 50 ,uM [1-_4C]-arachidonic acid for 10 min at 370 C results in the formation of two major radioactive ultraviolet light-absorbing peaks on RP-HPLC (figure 1). Radioactive peaks were also evident at the origin, but were identified as PGE2 and 6-keto-PGF10, known products of arachidonate metabolism in endothelial cells. I-3 Peak I is also known from previous work to be the PGH2 hydrolysis product HHT. Peak II is a new product with a retention time of 20.5 min that chromatographs in the monohydroxy arachidonate region (figure 1, A) . Boiling the endothelial cells for 10 min completely inhibited the synthesis of both peaks I and II ( figure 1, B) . Preincubation of the endothelial cells with 1 mM aspirin, a cyclooxygenase inhibitor, inhibited peak I formation, but did not significantly influence peak II synthesis ( figure 1, C) . Incubation with the lipoxygenase inhibitor NDGA at a concentration of 30 ,uM inhibited peak II formation approximately 85%, and inhibited peak I synthesis about 30% ( figure 1, D) .
To determine the structural identity of peak II, the molecule was esterified with diazomethane, derivitized to the trimethylsilyl ether, and analyzed by GC/MS.' The methyl ester, trimethylsilyl ether derivative of peak II gave prominent ions at 225 (base peak), 316 (M'-90), 335 (M+-71), 375 (M+-31), 391 (M+-15), and the molecular ion at 406. This mass spectrum is identical to the published mass spectrum of the methyl ester, trimethylsilyl ether derivative of 15 figure 4, A) . Peaks I, II, III, and IV were found to have RP-HPLC retention times (14.5 to 21.0 min) analogous to those of dihydroxy arachidonate molecules. Incubation of endothelial cells at 1000 C for 10 min completely inhibited the formation of peaks I to IV ( figure 4, B) . Ultraviolet spectrophotometry revealed that each peak had a conjugated triene structure with identical ultra violet maxima at 258, 268, and 279 nm, and esterifica- are also identical and reveal a conjugated triene system with absorption maxima at 258, 268, and 279 nm. Compounds I and III have retention times on RP-HPLC and ultraviolet spectra that are identical to those of diastereomeric (8R, 1 5S)-and (8S, 15S)-dihydroxy acids formed from the hydrolysis of synthetic 14,15 LTA4. These compounds were detected by Maas et al.'3 in incubations of 15-HPETE with porcine leukocytes, and are thought to be formed by the incorporation of oxygen from water at C-8. Peak I was identified as (8R, 1 5S)-dihydroxy-5-cis-9,1 1, 1 3-transeicosatetraenoic acid, and peak III as (8S,15S)-dihydroxy-5-cis-9, 11,13-trans-eicosatetraenoic acid. 13 These hydrolysis products correspond to the 5,12-dihydroxy acids formed nonenzymatically from LTA4 via acid-catalyzed formation of a carbonium ion. 20 The mechanism of formation of compounds II and IV is not clear. Originally, an attack on the 14,15-LTA4 epoxide by either hydroxyl radical or superoxide anion by direct nucleophilic attack or by electron transfer was proposed. 14 More recently, a reaction scheme was proposed that has many mechanistic features in common with the 12-lipoxygenase.2' The mechanism involves the removal of the pro(S) hydrogen aTt C-10, and migration of the radical to C-14. This radical centers on C-14, then reacts with the carbon-bound hydroperoxy oxygen with homolytic cleavage of the oxygen-oxygen bond to form 14, 15-LTA4. In addition, according to this hypothesis, migration of a radical centered on C-10 in the opposite direction gives antarafacial addition of oxygen at C-8, leading to the formation of compounds II and IV.21 Since we have indirect evidence by HPLC of 12-HETE formation, a similar mechanism in endothelial cells is possible. It is believed that compound II is (8S, 1 5S)-dihydroxy-5-cis-9-trans-1 1 -cis-1 3-transeicosatetraenoic acid, and compound IV is (8R, 15S)-dihydroxy-5 -cis-9-trans-1 1 -cis-1 3-trans-eicosatetraenoic acid. 13 Although the absolute stereochemistry of the 8,15-diHETE molecules produced by endothelial cells is not known, our data suggest that 14, 15-LTA4 is produced from 15-HPETE, and that two enzymatic (II, IV) and two nonenzymatic peaks (I, III) are synthesized from 15-HPETE by human endothelial cells. At the present time we do not know if these molecules are produced by a single enzyme or a sequence of enzymes. It is possible that 14, 15-LTA4 could be formed by interaction with hemoproteins (Cyt P-450, Cyt c) instead of by a specific 14,15-LTA4 synthase.'2 23 However, the high concentrations of these proteins that would be required to catalyze 14, 15-LTA4 synthesis from 15-HPETE make this an unlikely alternative.
The presence of 1 1-, 12-, and 15-OH arachidonate derivatives in vascular smooth muscle cells is well documented, and a recent report showed that 12-HETE was chemotactic for smooth muscle cells. ' With both smooth muscle and endothelial cells displaying hydroxy fatty acid metabolism, the interesting possibility of transcellular metabolism between these two vascular cells as well as circulating cells cannot be ignored. Although the physiologic significance of 15-HETE and 8, 15-diHETE in endothelial cells is not known, the presence of these molecules in our experiments suggests that the involvement of 15-lipoxygenase products in neutrophil-endothelial cell and platelet-endothelial cell interactions warrants further study.
